Holen Sie sich die Stockscreener-App
13.87
2.59%
0.38
Schlusskurs vom Vortag:
$13.49
Offen:
$13.56
24-Stunden-Volumen:
91,726
Relative Volume:
0.49
Marktkapitalisierung:
$937.90M
Einnahmen:
$-9,000
Nettoeinkommen (Verlust:
$-68.03M
KGV:
-13.21
EPS:
-1.05
Netto-Cashflow:
$-44.76M
1W Leistung:
+6.54%
1M Leistung:
-10.48%
6M Leistung:
-19.95%
1J Leistung:
-26.11%
1-Tages-Spanne:
$13.41
$13.98
1-Wochen-Bereich:
$13.09
$13.98
52-Wochen-Spanne:
$12.56
$25.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
Firmenname
Pulse Biosciences Inc
Sektor
Telefon
510-906-4600
Adresse
3957 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie PLSE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
13.84 | 914.18M | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
560.62 | 200.96B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
189.12 | 54.09B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
78.92 | 38.74B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
247.01 | 36.50B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
WST
West Pharmaceutical Services Inc
|
266.91 | 19.36B | 2.96B | 487.70M | 344.00M | 6.6758 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Eingeleitet | Oppenheimer | Outperform |
| 2021-07-27 | Eingeleitet | Stephens | Overweight |
| 2021-03-11 | Eingeleitet | Maxim Group | Buy |
| 2021-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-12 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Pulse Biosciences Inc Aktie (PLSE) Neueste Nachrichten
Pulse Biosciences, MD Anderson, launch study of novel ablation technology for thyroid cancer - Medical Economics
Pulse Biosciences to evaluate PFA in treating thyroid cancer - MassDevice
Pulse Biosciences (PLSE) Collaborates with MD Anderson for Thyro - GuruFocus
Pulse Biosciences to begin thyroid cancer treatment study in 2026 By Investing.com - Investing.com Australia
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology - Yahoo Finance
With 73% ownership, insiders at Pulse Biosciences, Inc. (NASDAQ:PLSE) are pretty optimistic and have been buying recently - Yahoo Finance UK
Is Pulse Biosciences Inc. stock a buy before product launchesDollar Strength & AI Enhanced Trading Alerts - Newser
Bull Run: Is Pulse Biosciences Inc stock near bottom after declineJuly 2025 Retail & Stock Portfolio Risk Management - BỘ NỘI VỤ
How cyclical is Pulse Biosciences Inc. (6L8) stock compared to rivalsRecession Risk & Weekly High Return Forecasts - Newser
Is Pulse Biosciences Inc. stock a safe investment in uncertain markets2025 Institutional Moves & Real-Time Volume Analysis - Newser
Trading Systems Reacting to (PLSE) Volatility - news.stocktradersdaily.com
Is Pulse Biosciences Inc. stock a defensive play in 2025Trade Volume Report & Safe Entry Zone Identification - Newser
Is Pulse Biosciences Inc. stock near bottom after declineDay Trade & Reliable Breakout Stock Forecasts - Newser
Will Pulse Biosciences Inc. (6L8) stock benefit from Fed rate cutsVolume Spike & Community Trade Idea Sharing - Newser
How dovish Fed policy supports Pulse Biosciences Inc. (6L8) stockJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Pulse Biosciences (PLSE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Will Pulse Biosciences Inc. (6L8) stock benefit from mergersJuly 2025 Selloffs & Consistent Income Trade Ideas - Newser
Value Recap: Can Pulse Biosciences Inc. stock beat market expectations this quarter - moha.gov.vn
Operating cash flow per share of Pulse Biosciences, Inc. – SWB:6L8 - TradingView
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 21, 2025 - BioSpace
How Pulse Biosciences Inc (PLSE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Is Pulse Biosciences Inc. (6L8) stock in buy zone after pullbackJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com
Is Pulse Biosciences Inc. stock supported by innovation pipelineJuly 2025 Reactions & Real-Time Stock Movement Alerts - newser.com
Will Pulse Biosciences Inc. stock maintain momentum in 20252025 Performance Recap & Real-Time Volume Analysis - newser.com
Top chart patterns to watch in Pulse Biosciences Inc.July 2025 Price Swings & High Conviction Trade Alerts - newser.com
How high can Pulse Biosciences Inc. stock goJuly 2025 Macro Moves & Weekly High Return Opportunities - newser.com
What recovery options are there for Pulse Biosciences Inc.Entry Point & Free AI Powered Buy and Sell Recommendations - newser.com
Can Pulse Biosciences Inc. (6L8) stock resist broad market declinesWatch List & Growth Focused Entry Point Reports - newser.com
Why hedge funds are buying Pulse Biosciences Inc. stockJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
Will Pulse Biosciences Inc. (6L8) stock draw ESG focused fundsTrend Reversal & Daily Volume Surge Signals - newser.com
Why Pulse Biosciences Inc. (6L8) stock benefits from AI revolutionEarnings Risk Report & Risk Managed Investment Entry Signals - newser.com
Is Pulse Biosciences Inc. stock positioned for digital transformation2025 Earnings Impact & Low Volatility Stock Recommendations - newser.com
Real time alert setup for Pulse Biosciences Inc. performanceMarket Movement Recap & Low Risk Investment Opportunities - newser.com
Using fundamentals and technicals on Pulse Biosciences Inc.Analyst Downgrade & Consistent Return Strategy Ideas - newser.com
Is Pulse Biosciences Inc. (6L8) stock considered safe haven2025 Short Interest & Fast Moving Trade Plans - newser.com
Finanzdaten der Pulse Biosciences Inc-Aktie (PLSE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pulse Biosciences Inc-Aktie (PLSE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Oct 02 '25 |
Sale |
18.53 |
4,600 |
85,238 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Option Exercise |
1.53 |
400 |
612 |
43,698 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Sale |
18.49 |
20,000 |
369,800 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Sale |
18.48 |
400 |
7,392 |
43,298 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Option Exercise |
4.00 |
181,534 |
726,136 |
284,406 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Option Exercise |
4.00 |
25,000 |
100,000 |
147,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Sale |
16.28 |
25,000 |
407,000 |
122,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Sale |
16.21 |
20,000 |
324,200 |
122,872 |
0.39%
2.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):